Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial
- DOI
- 10.1038/s41467-025-63579-9
- Published
- 2025-09-29
- Container
- Nature Communications
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1038/s41467-025-63579-9,
title = {Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial},
author = {Jong Chul Park and Brendan Curti and Marcus Butler and Eric Wehrenberg-Klee and Joseph Elassal and Robert Tighe and Sailaja Battula and Gail Iodice and Howard L. Kaufman and John M. Kirkwood},
year = {2025},
journal = {Nature Communications},
doi = {10.1038/s41467-025-63579-9},
url = {https://doi.org/10.1038/s41467-025-63579-9}
}RIS
TY - JOUR TI - Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial AU - Jong Chul Park AU - Brendan Curti AU - Marcus Butler AU - Eric Wehrenberg-Klee AU - Joseph Elassal AU - Robert Tighe AU - Sailaja Battula AU - Gail Iodice AU - Howard L. Kaufman AU - John M. Kirkwood PY - 2025 JO - Nature Communications DO - 10.1038/s41467-025-63579-9 UR - https://doi.org/10.1038/s41467-025-63579-9 ER -
APA
Park, J. C., Curti, B., Butler, M., Wehrenberg-Klee, E., Elassal, J., Tighe, R., Battula, S., Iodice, G., Kaufman, H. L., & Kirkwood, J. M. (2025). Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial. Nature Communications. https://doi.org/10.1038/s41467-025-63579-9
Source records
- crossref · retrieved 2026-09-26T04:46:19.626Z